Оптимальное лечение артериальной гипертониии ишемической болезни сердца: аргументы в пользукомбинации периндоприла аргинина и амлодипина

1. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–23.
2. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52.
3. Kaplan NM, Clinical Hypertension. Philadelphia, PA: Lippincott, Williams & Wilkins, 2006.
4. Карпов Ю.А., Шальнова С.А., Деев А.Д. от имени участников программы ПРЕМЬЕРА. Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) – безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология 2006; 6: 32–8.
5. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр). Кардиоваск. тер. и проф. 2008; 6 (Прил. 2).
6. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
7. Pepine CJ, Handberg-Thurmond E, Marks P et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an internet – based randomized trial in coronary artery disease patients with hypertension. JACC 1998; 32: 1228–37.
8. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006; 27: 1341–81.
9. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
10. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362; 782–8.
11. Карпов Ю.А. Периндоприл аргинин: новая соль ингибитора АПФ расширяет возможности применения. Кардиоваск. тер. и проф. 2008; 6: 64–72.
12. Perindopril: a major contribution to the prevention and treatment of cardiovascular disease. Edited by Ferrari F & Fox KM. Volters Kluwer, 2008.
13. The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
14. Ferrari R. for the PREAMI investigators. Effects of ACE inhibition with perindopril on left ventricular remodeling and clinical outcome. Arch Intern Med 2006; 166: 659–66.
15. Cleland JGF, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF). Eur Heart J 2006; 27: 2338–45.
16. ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828–40.
17. Deckers JW, Goedhart DM, Boersma E et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Hypertens J 2006; 27.
18. Remme WJ, Deckers JW, Fox KM et al. Secondary prevention of coronary disease with ACE inhibition – does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc Drug Ther 2008. DOI 10.1007/s10557–008–6143–6.
19. Bots ML, Remme WJ, Luscher TF et al. ACE inhibition and endothelial function: mail findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007; 21: 269–79.
20. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression (from rhe PERindopril's Prospective Effect on Coronary a Theroslerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007; 100: 159–63.
21. Ceconi C, Fox K, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
22. Карпов Ю.А. Ингибиторы АПФ у больных ИБС: при высоком риске осложнений или всем. Кардиология 2005; 9: 4–10.
23. Brugts JJ, Boersma E, Deckers JW et al. Abstract 5066: The treatment effect of perindopril is consistent in all patients with vascular disease: a combined analysis of three perindopril trials. Circulation 2008; 118: S1138.
24. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
25. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–25.
26. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981–97.
27. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet 2004; 363: 2022–31.
28. Jamerson KA, Weber MA, Bakris GL et al on behalf of the ACCOMPLISH investigators. Benazepril plus amlodipine or hydrochlorotiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–28.
29. Bertrand M, Sever P. Synergistic effect of perindopril and calcium channel blookers in prevention of cardiac events and death in coronary artery disease patients: analysis from the EUROPA study (abstract 3267). Congress of the European Society of Cardiology (ESC). Munich, 2008.
30. Pepine C, Handberg EM, Cooper-deHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.
31. PEACE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–68.
32. Ceconi C, Francolini G, Olivares A et al. Angiotensin-converting enzyme (ACE) inhibitors heve different selectivity for bradykinin binding sites of human soman somatic ACE. Eur J Pharmacol 2007; 577: 1–6.
33. Poole-Wilson PA, Lubsen J, Kirvan B-A et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet 2004; 364: 849–57.
34. Brown M, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
35. Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice. Results from the STRONG Prospective, Observational, Multicenter Study. Am J Cardiovasc Drugs 2009; 9 (3): 136–42.
Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication complincec a meta-analysis. Am J Med 2007; 120 (8): 713–9.